The Lancet Neurology: July 11, 2013

Paul Hagerman discusses a Review which highlights the latest clinical and molecular understanding of the FMR1 mutation and FXTAS. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Om Podcasten

Editors at The Lancet Neurology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from sleep habits to amyloid biomarkers in Alzheimer’s, the diagnosis and classification of optic neuritis to treatment of Creutzfeldt-Jakob disease, and more.